Biosensors celebrates a year of achievement at TCT with an expanded product portfolio

Published on:

Biosensors International is celebrating a year of significant achievement with an expanded product portfolio, offering physicians a broader range of treatment options to improve patient outcomes.

Since TCT 2012, the company has revitalized its core offering with the launch of BioMatrix NeoFlex(tm), a DES with exceptional performance in complex lesions and challenging anatomies; expanded its range of dedicated bifurcation stents with Axxess(tm) 4.0x9, designed to treat larger, shorter and wider-angulated bifurcations; complemented its stent portfolio by introducing a range of drug-eluting balloon dilation catheters for the treatment of both coronary and peripheral artery disease; and re-established its leadership in coronary stent technology with the introduction of BioFreedom(tm), the world's first polymer-free stent coated with Biolimus A9(tm).

In May 2013 Biosensors took a significant step towards revolutionizing patient care with the acquisition of functional imaging company Spectrum Dynamics, whose expertise will help cath labs determine which patients require a stent without the need for diagnostic angiography. Spectrum Dynamics's technology is faster than conventional functional imaging, requires less contrast medium to be injected, and can deliver up to 10 times the sensitivity and twice the spatial resolution.

"We have come further than we could possibly have imagined since last year's TCT", commented Jeffrey B. Jump, President of Biosensors' Cardiovascular Division. "Over the last twelve months we have revamped the leading biodegradable polymer DES, increased the applications for our specialist bifurcation stent, offered cath labs a wider choice of treatment options with a range of drug-eluting balloons and acquired technology with the potential to fundamentally change the way that interventional cardiology is practiced: so who knows what we can achieve over the next twelve months!"

Visitors to TCT can find full details on Biosensors' expanded portfolio at Booth 1607 in Hall B.

Related Content

Cardiologists reflect on developing primary PCI in face of criticism and pushback
How TAVR valve choice impacts outcomes when treating type 1 bicuspid AS
IVUS-guided PCI reduces risks in patients with diabetes
Medtronic using AI to identify more TAVR patients in need
SAVR linked to higher 10-year survival rate than TAVR for low-risk patients
LAAC with Watchman FLX reduces bleeding risks after AFib ablation

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."